Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of the American College of Cardiology

• Publication date

  2015-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2015.07.020PMID 26361154
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of plasma Lp-PLA2 activity on the progression of aortic stenosis: the PROGRESSA study.

  2015influential reference
• Impact of statins on serial coronary calcification during atheroma progression and regression.

  2015cited by this paper
• 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans.

  2014cited by this paper
• Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.

  2014cited by this paper
• Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization.

  2014cited by this paper
• New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis.

  2014cited by this paper
• Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a).

  2014cited by this paper
• 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis: A Prospective Mendelian Randomization Study and Replication in a Case–Control Cohort

  2014cited by this paper
• Progression of aortic valve stenosis is associated with bone remodelling and secondary hyperparathyroidism in elderly patients--the COFRASA study.

  2013cited by this paper
• Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis.

  2013cited by this paper
• Adaptive immunity in atherogenesis: new insights and therapeutic approaches.

  2013cited by this paper
• Genetic associations with valvular calcification and aortic stenosis.

  2013cited by this paper
• Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)1

  2013cited by this paper
• Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).

  2012cited by this paper
• Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events.

  2012cited by this paper
• A time course investigation of the statin paradox among valvular interstitial cell phenotypes.

  2012cited by this paper
• Inhibition of Bone Morphogenetic Protein Signaling Reduces Vascular Calcification and Atherosclerosis

  2012cited by this paper
• Guidelines on the management of valvular heart disease (version 2012).

  2012cited by this paper
• Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy.

  2012influential reference
• The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification.

  2011cited by this paper
• Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update.

  2011cited by this paper
• Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

  2011influential reference
• Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice.

  2011cited by this paper
• Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial

  2010cited by this paper
• Oxidized low-density lipoprotein, angiotensin II and increased waist cirumference are associated with valve inflammation in prehypertensive patients with aortic stenosis.

  2010cited by this paper
• Age-related differences in the pathogenesis of calcific aortic stenosis: the potential role of resistin.

  2010cited by this paper
• Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.

  2010cited by this paper
• Oxidized low density lipoprotein decreases Rankl‐induced differentiation of osteoclasts by inhibition of Rankl signaling

  2009cited by this paper
• Aortic stenosis.

  2009cited by this paper
• Congenital aortic stenosis in adults: rate of progression and predictors of clinical outcome.

  2009cited by this paper
• Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

  2009cited by this paper
• Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis

  2007cited by this paper
• Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study

  2007cited by this paper
• Guidelines on the management of valvular heart disease.

  2007cited by this paper
• Congenital aortic stenosis in adults: rate of progression and predictors of clinical outcome.

  2007cited by this paper
• Association Between Plasma LDL Particle Size, Valvular Accumulation of Oxidized LDL, and Inflammation in Patients With Aortic Stenosis

  2007cited by this paper
• Burden of valvular heart diseases: a population-based study.

  2006cited by this paper
• Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology

  2006cited by this paper
• Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.

  2005cited by this paper
• Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.

  2003cited by this paper
• Stimulation of bone formation in vitro and in rodents by statins.

  1999cited by this paper
• Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis.

  1996cited by this paper
• Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a).

  1986cited by this paper
• Aortic stenosis.

  1960cited by this paper

• Decoding calcific aortic valve disease: superior predictive power of time-weighted lipoprotein(a).

  2026cites this paper
• Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease

  2026cites this paper
• Oxidised lipoproteins and the risk of type 2 diabetes mellitus: A 5-year cohort study on β-cell dysfunction and prediabetes progression.

  2026cites this paper
• Interplay between medical and interventional therapies in valvular heart disease and heart failure: an expert opinion paper.

  2026cites this paper
• Analytical validation of monoclonal antibody-based ELISA methods for OxPL-apoB and OxPL-apo(a)

  2026cites this paper
• Clinical Update on the Intersection of Lipoprotein(a) and Calcific Valve Disease

  2025influential citation
• Mineral composition and ratios in aortic valves, serum, and epicardial fat among patients with aortic stenosis undergoing aortic valve replacement

  2025cites this paper
• Unveiling Lipoprotein(a): A New Frontier in Heart Health

  2025cites this paper
• The predictive value of serum lipoprotein(a) level for new-onset aortic valve calcification in patients with coronary artery disease

  2025cites this paper
• Statins—Their Effect on Lipoprotein(a) Levels

  2025cites this paper
• Lipoprotein(a) and Its Role in Peripheral Arterial Disease: A Narrative Review

  2025cites this paper
• Anti‐Malondialdehyde Low‐Density Lipoprotein Antibodies and Valvular Calcification: A Substudy of the SCOT‐HEART Trial

  2025cites this paper
• Eicosapentaenoic acid limits the more rapid oxidation of lipoprotein(a) compared with other apolipoprotein B particles

  2025cites this paper
• Serum metabolic profiling in rheumatic heart disease and degenerative aortic stenosis

  2025cites this paper
• Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis

  2025cites this paper
• Could the Hemodynamic Progression of Aortic Valve Stenosis be Slowed Pharmacologically? The Unsolved Dilemma

  2025cites this paper
• Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease

  2025cites this paper
• Novel Circulating Biomarkers in Aortic Valve Stenosis

  2025cites this paper
• A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions

  2025cites this paper
• Structure-guided dissection of the genetic variations within human LPA locus and its role in the development of cardiovascular diseases.

  2025cites this paper
• The role of elevated lipoprotein(a) in aortic valve disease: a systematic review

  2025cites this paper
• A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions

  2025cites this paper
• Shared Risk Factors and Molecular Mechanisms Between Aortic Stenosis and Atherosclerosis: A Rationale for Therapeutic Repositioning

  2025cites this paper
• Combined Raman Microscopy and Transmission Electron Microscopy shows the co-existence of whitlockite crystals and carbonated hydroxyapatite-mineralized collagen fibrils in human calcified aortic valves

  2025cites this paper
• Lipoprotein(a) and panvascular disease

  2025cites this paper
• Risk Stratification of Patients With Moderate Aortic Stenosis Using Aortic Valve Calcium

  2025cites this paper
• Diabetes and elevated plasma glucose in heart valve calcification and disease: the Copenhagen General Population Study.

  2025cites this paper
• Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization.

  2025cites this paper
• Does statin matter when it comes to Lipoprotein(a) levels?

  2025cites this paper
• Co-Occurrence of Aortic Stenosis and Coronary Artery Disease: Facing Challenges Before, During, and After Transcatheter Aortic Valve Replacement

  2025cites this paper
• Valvular calcification in chronic kidney disease: new insights from recent clinical and preclinical studies

  2025cites this paper
• Association between lipoprotein(a) and long-term prognosis in patients receiving transcatheter aortic valve replacement.

  2025cites this paper
• A Little Calcium Goes a Long Way: Rethinking Early Calcific Aortic Valve Disease.

  2025cites this paper
• Between Scylla and Charybdis - Enigmatic role of lipoprotein(a) in atherosclerotic cardiovascular disease and type 2 diabetes mellitus.

  2025cites this paper
• Lipoprotein(a): An Underappreciated Inherited Risk Factor for Atherosclerosis, Aortic Stenosis, and Abdominal Aortic Aneurysm.

  2025cites this paper
• The Effect of Low, Moderate, and High Doses of Rosuvastatin on Lipoprotein(a) Levels in Hyperlipidemic Patients with Impaired Fasting Glucose: A Post-Hoc Analysis.

  2025cites this paper
• A collagen-based laboratory model to mimic sex-specific features of calcific aortic valve disease.

  2025cites this paper
• Lipoprotéine(a) : physiopathologie et indications du dosage dans les maladies cardiovasculaires

  2025cites this paper
• Lipoprotein (a) Distribution in Aortic Stenosis Patients

  2025cites this paper
• Lipoprotein(a) and Aortic Valve Stenosis: From Pathophysiology to Emerging Pharmacological Agents

  2025cites this paper
• Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis

  2025cites this paper
• Research Status of the Relationship between Lipoprotein(a) and Cardiovascular Diseases

  2025cites this paper
• [Aortic Valve Stenosis and Acute Coronary Syndrome. Obvious Answers to Non-Obvious Questions].

  2025cites this paper
• Lp(a): A clinical review.

  2025cites this paper
• Elevated lipoprotein(a) and progression of aortic stenosis measured by Doppler echocardiography: A population‐based cohort study

  2025cites this paper
• Associations of aortic valve area and calcification with diastolic heart function and high lipoprotein(a) levels in a population study

  2025cites this paper
• Insights into preclinical models of calcific aortic valve disease and their translational potential

  2025cites this paper
• Aortic Stenosis: Diagnosis, Molecular Mechanisms and Therapeutic Strategies—A Comprehensive Review

  2025cites this paper
• Valvular oxidized phospholipids correlate with severity of human aortic valvular stenosis.

  2025cites this paper
• MALDI-TOF MS Detection of Oxidized Major Phospholipids in Biological Samples Using Conventional Matrices and 1‑Pyrenebutyric Hydrazide

  2025cites this paper
• Unleashing the potential of exercise: conquering cardiovascular disease by targeting inflammasome activation

  2025cites this paper
• Oxidized phospholipid dynamics in the early post-infarction period: Effects of PCSK9 inhibition with evolocumab.

  2025cites this paper
• Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies

  2025cites this paper
• Lipoprotein (a) as a Cardiovascular Risk Factor in Controversial Clinical Scenarios: A Narrative Review

  2024cites this paper
• Moderate Aortic Stenosis—Advanced Imaging, Risk Assessment, and Treatment Strategies

  2024cites this paper
• Oxidized Phospholipids and Calcific Aortic Valvular Disease.

  2024cites this paper
• Lipoprotein (a): Underrecognized Risk with a Promising Future

  2024cites this paper
• Aortic Valve Embryology, Mechanobiology, and Second Messenger Pathways: Implications for Clinical Practice

  2024cites this paper
• Lipoprotein(a): Emerging insights and therapeutics

  2024influential citation
• Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities

  2024cites this paper
• Advances in Pharmacological Approaches for Managing Hypercholesterolemia: A Comprehensive Overview of Novel Treatments

  2024cites this paper
• Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review

  2024cites this paper
• Lp(a) and Accelerated Progression of Aortic Stenosis

  2024cites this paper
• Extracellular matrix dynamics in aortic valve health and disease: Insights into fibrocalcific remodeling and creation of biomimetic platforms

  2024cites this paper
• Calcific aortic valve disease and cardiometabolic triggers: an explanation behind progression of aortic valvular disease and failure of medical therapy interventions

  2024cites this paper
• Elevated Lp(a): Guidance for Identifying and Managing Patients

  2024cites this paper
• Effectiveness of cascade screening for elevated lipoprotein(a), an underdiagnosed family disorder

  2024cites this paper
• Association of Lipoprotein(a) With Severe Degenerative Aortic Valve Stenosis

  2024cites this paper
• Analysis of risk factors for aortic stenosis in patients with familial hypercholesterolemia

  2024cites this paper
• Unmet needs and knowledge gaps in aortic stenosis: A position paper from the Heart Valve Council of the French Society of Cardiology.

  2024cites this paper
• Variation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size.

  2024cites this paper
• Current Management and Therapy of Severe Aortic Stenosis and Future Perspective

  2024cites this paper
• Identifying People at High Risk for Severe Aortic Stenosis: Aortic Valve Calcium Versus Lipoprotein(a) and Low-Density Lipoprotein Cholesterol

  2024cites this paper
• Molecular Features of Calcific Aortic Stenosis in Female and Male Patients

  2024cites this paper
• Genetics and Pathophysiological Mechanisms of Lipoprotein(a)‐Associated Cardiovascular Risk

  2024cites this paper
• European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics.

  2024cites this paper
• Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis.

  2024cites this paper
• Research Hotspots and Development Trends on Apolipoprotein B in the Field of Atherosclerosis: A Bibliometric Analysis

  2024cites this paper
• Unraveling the Enigma of Moderate Aortic Stenosis: Challenges and Future Prospects

  2024cites this paper
• Therapeutic Potential of Lipoprotein(a) Inhibitors

  2024cites this paper
• A study protocol to characterise pathophysiological and molecular markers of rheumatic heart disease and degenerative aortic stenosis using multiparametric cardiovascular imaging and multiomics techniques

  2024cites this paper
• Lipoprotein(a) Levels in Severe Aortic Stenosis Referred for Transcatheter Aortic Valve Implantation Compared to Controls

  2024cites this paper
• The Role of Lipoprotein(a) in Peripheral Artery Disease

  2024cites this paper
• AI-Enhanced Prediction of Aortic Stenosis Progression

  2024cites this paper
• LP(a): The new marker of high cardiovascular risk.

  2024cites this paper
• Role of follistatin-like 1 levels and functions in calcific aortic stenosis

  2023cites this paper
• Consideration and Application of Lipoprotein(a) in the Risk Assessment of Atherosclerotic Cardiovascular Disease Risk in Adults

  2023cites this paper
• Lp(a) and risk of cardiovascular disease - A review of existing evidence and emerging concepts.

  2023cites this paper
• The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis

  2023cites this paper
• Understanding the driving mechanisms of bioprosthetic valve degeneration

  2023cites this paper
• Lp(a) in the Pathogenesis of Aortic Stenosis and Approach to Therapy with Antisense Oligonucleotides or Short Interfering RNA

  2023cites this paper
• Oxidized phospholipids in cardiovascular disease

  2023cites this paper
• Treatment of Lp(a): Is It the Future or Are We Ready Today?

  2023cites this paper
• Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives

  2023cites this paper
• Left ventricular hypertrophy, diastolic dysfunction and right ventricular load predict outcome in moderate aortic stenosis

  2023cites this paper
• Role of lipoprotein(a) concentrations in bioprosthetic aortic valve degeneration

  2023cites this paper
• Lipoprotein (a) is a risk factor of aortic valve calcification in patients with a risk of atherosclerosis.

  2023cites this paper
• Lipoprotein(a) and calcific aortic valve disease: current evidence and future directions

  2023cites this paper
• Association Between Remnant Cholesterol and Progression of Bioprosthetic Valve Degeneration.

  2023cites this paper
• Lipoprotein(a) As a Potential Predictive Factor for Earlier Aortic Valve Replacement in Patients with Bicuspid Aortic Valve

  2023cites this paper